A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

Phase 1

• Conditions: Transfusion-Dependent Alpha- or Beta-Thalassemia; MedDRA version: 22.0Level: LLTClassification code 10081904Term: Transfusion dependent thalassemiaSystem Organ Class: 100000004850; Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

• Registration Number: EUCTR2021-000212-34-NL
• Lead Sponsor: Agios Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-29
• Last Update Posted: 26 September 2023

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. =18 years of age at the time of providing informed consent.
2. Documented diagnosis of thalassemia (ß-thalassemia with or without a-globin gene mutations, HbE/ß-thalassemia, or a-thalassemia/HbH disease) based on DNA analysis
from the subject’s medical record. If this information is not available from the subject’s medical record, DNA analysis can be performed by a local laboratory during the
Screening Period. If a local laboratory is unable to perform the test, results from the comprehensive a- and ß-globin genotyping performed by the study central laboratory can be used.
3. Transfusion dependent, defined as 6 to 20 RBC units transfused and a =6-week transfusion-free period during the 24-week period before randomization.
4. If taking hydroxyurea, the hydroxyurea dose must be stable for =16 weeks before randomization.
5. Women of childbearing potential (WOCBP) must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method.
6. Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 234
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

1. Pregnant, breastfeeding, or parturient.
2. Documented history of homozygous or heterozygous HbS or HbC.
3. Prior exposure to gene therapy or prior bone marrow or stem cell transplantation.
4. Currently receiving treatment with luspatercept; the last dose must have been administered =36 weeks before randomization.
5. Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered =36 weeks before randomization.
6. History of malignancy (active or treated) =5 years before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.
7. History of active and/or uncontrolled cardiac or pulmonary disease =6 months before providing informed consent, including but not limited to:
a. New York Heart Association Class III or IV heart failure or clinically significant dysrhythmia
b. Myocardial infarction or unstable angina pectoris; hemorrhagic, embolic, or thrombotic stroke; deep venous thrombosis; or pulmonary or arterial embolism
c. Heart rate–corrected QT interval using Fridericia’s method =450 milliseconds (males) or =470 milliseconds (females), except for right or left bundle branch block
d. Severe pulmonary fibrosis as defined by severe hypoxia, evidence of right-sided heart failure, and radiographic pulmonary fibrosis >50%
e. Severe pulmonary hypertension as defined by severe symptoms associated with hypoxia, right-sided heart failure, and oxygen indicated
8. Hepatobiliary disorders, including but not limited to:
a. Liver disease with histopathological evidence of cirrhosis or severe fibrosis
b. Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary)
c. History of drug-induced cholestatic hepatitis
d. Aspartate aminotransferase >2.5 × upper limit of normal (ULN); unless due to hemolysis and hepatic iron deposition) and alanine aminotransferase >2.5 × ULN (unless due to hepatic iron deposition)
9. Estimated glomerular filtration rate <45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation.
10. Nonfasting triglycerides >440 mg/dL (5 mmol/L).
11. Active infection requiring systemic antimicrobial therapy at the time of providing informed consent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered =7 days before randomization.
12. Positive test for hepatitis C virus (HCV) antibody (Ab) with evidence of active HCV infection, or positive test for hepatitis B surface antigen.
13. Positive test for HIV-1 Ab or HIV-2 Ab.
14. History of major surgery (including splenectomy) =6 months before providing informed consent and/or a major surgical procedure planned during the study.
15. Current enrollment or past participation (=12 weeks before administration of the first dose of study drug or a time frame equivalent to 5 half-lives of the investigational treatment, whichever is longer) in any other clinical study involving an investigational treatment or device.
16. Receiving strong cytochrome P450 (CYP)3A4/5 inhibitors that have not been stopped for =5 days or a time frame equivalent to 5 half-lives (whichever is longer), or strong CYP3A4 inducers that have not been stopped for =4 weeks or a time frame equivalent to 5 half-lives (whichever is longer), before randomization.
17. Receivi

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified